7/28/2022

speaker
Operator
Conference Operator

Greetings. Welcome to Ametis' second quarter 2022 earnings call. At this time, all participants are in listen-only mode. The question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note, this conference is being recorded. At this time, I'll turn the conference over to Nick Moscato with Investor Relations. Nick, you may now begin.

speaker
Nick Moscato
Investor Relations

Thank you, Operator, and welcome to the Emeticis Investor Conference call to discuss the results of the second quarter ended June 30, 2022. A copy of our press release, supplemental slides, and related Form 8K filings with the SEC are available on the Investor Relations page of our website. Speaking on today's call from Emeticis will be President and Chief Executive Officer Chris Gerrard and Executive Vice President and Chief Financial Officer Scott Ginn. Also joining us is Dave Kimmerly, Chief Legal and Government Affairs Officer. Before we get started with our calls, I would like to remind everyone that statements made on this conference call today may constitute forward-looking statements and are protected under the safe harbor of the Private Securities Litigation Reform Act. These forward-looking statements are based on information available to Emeticis today. The company assumes no obligation to update information provided on this call to reflect subsequent events other than as required under applicable securities laws. These forward-looking statements may involve a number of risks and uncertainties, which may cause the company's results or actual outcomes to differ materially from such statements. These risks and uncertainties include factors detailed in our SEC filings, including our Forms 10-K, 10-Q, and 8-K. In addition, as required by SEC Regulation G, a reconciliation of any non-GAAP measure mentioned during our call to the most comparable GAAP measures will be available in our Forms 10-K, 10-Q, and 8-K. Thank you. And now I'll turn the call over to President and CEO, Chris Gerard.

speaker
Chris Gerrard
President & CEO

Thanks, Nick, and thanks to everyone for joining us. Today, Amedisys announced our second quarter 2022 results. Before we get into the performance update, I want to give a heartfelt thank you to all Amedisys employees. The work you do and the care you perform on a daily basis is an inspiration, and I am truly grateful for all that you do. The topic on everyone's mind has been the proposed home health rule for 2023. As most of you know, on June 17, CMS released the 2023 Home Health Proposed Rate Update, which detailed a reduction to overall home health payments by an aggregate amount of 4.2%. As you are all aware, the driver behind this reduction is CMS's proposed permanent cut of 6.9% to the 30-day base payment rate. that was derived from a 7.69% permanent behavioral assumption adjustment. CMS has also proposed a market basket increase of 3.3%, reduced by a productivity adjustment of 0.4%, for a total market basket update of 2.9%. We do anticipate the market basket increasing for the final rule as CMS uses more recent data to provide for this inflationary update. albeit the methodology and data the CMS is using is woefully inadequate to capture the true inflationary impact that providers across all of healthcare are experiencing in providing care throughout the country every day. CMS also stated, but not formally proposed, that it is due to collect approximately $2 billion in overpayments from 2020 and 21 combined. Not surprisingly, Amedisys, along with the entire home health industry, strongly disagrees with CMS's assertions of an overspend of this magnitude. In fact, we believe there has been no overpayment at all. The budget neutrality methodology employed by the agency is extremely flawed. As we have in the past, Amedisys has been prepared to engage with CMS directly and alongside our colleagues in the home health industry. The proposed cuts based on behavior adjustments is unsound, And we were working on a comment letter that will thoroughly outline our position around the assumptions, our experience throughout the first two years of PDGM, and the impact of the ongoing pandemic. It is also confusing to us in the industry, as well as members of Congress and congressional staff, why CMS is making such a drastic cut to reimbursement during times of extraordinary inflation. With that being said, we have been preparing for this scenario and have been in discussions with our congressional champions for months to formulate a thoughtful legislative approach that prohibits CMS from instituting these drastic proposed cuts. On Monday, Senator Debbie Stabenow, Democrat from Michigan, and Senator Susan Collins, Republican from Maine, introduced Preserving Access to Home Health Act in the U.S. Senate, and we expect a companion bill to be introduced in the House in the coming days. Thank you to Senator Stabenow and Senator Collins for your bipartisan commitment to championing a pause to the potential cuts to home health agencies and maintaining access for home health patients. This legislation upon enactment would pause the implementation of any temporary or permanent adjustments to the base payment rate under the budget neutrality mandate of PDGM until 2026. This would allow time for the industry and CMS to work on a much more reasonable and predictable methodology that adequately measures the impact and transition from old HHRG 60-day payment system with the new PDGM 30-day payment system, as well as fully accounting for the impact that COVID-19 has had on utilization, patient mix, and the level of care provided by home health agencies. Based on limited data and information released by CMS to date, the proposed cut to reimbursement in 2023 appears to be the result of flawed methodology and lack of full recognition of current labor inflation. Now that the bill has been introduced, we, along with the industry, will continue explaining to staff and members of Congress the impact of the proposed cuts on home health agencies, patient access, and the need to pass this legislation by the end of the year. With that, let's jump into the segment performance, and we'll start with home health. For the quarter, home health same-store total admissions were flat. Lower utilization of home health benefit, largely driven by less total discharges to post-acute settings, coupled with elevated utilization of telehealth, and in some markets, clinical staffing challenges impacted our ability to grow during the quarter. On the quality front, I'm excited to announce that for the October 2022 preview, Our home health quality of patient care star score is 4.49 stars, with 100% of our care centers reaching four stars or greater. Quality has been and always will be core to all we do at Amedisys. And this continued improvement is really something all of us here at Amedisys are proud of. For the quarter, we performed 13.2 visits per episode, up .2 visits sequentially, and down one visit year over year. Our implementation and utilization of MediLogix has helped us to continue to make progress, optimizing the care we deliver to our patients, while constantly focusing on improving our quality scores. On clinical mix, in Q2, we achieved 48% LPN utilization and 53% PTA utilization. We have made tremendous progress on our clinical mix and will continue to increase our utilization of both LPNs and PTAs throughout the year. However, as we optimize visits per episode, increasing these percentages becomes more challenging. Now, moving on to hospice. For the quarter, hospice same-store admits grew 6% and ADC was slightly positive at 0.2%. This represents our first quarter of ADC growth since Q3 of 2020. Additionally, we saw a 2.5% sequential increase in ADC. Continued progress on the ADC front will help to drive performance in the second half of the year. As we continue to focus on both admission and ADC growth, we're going back and being more targeted in where we're adding our BD reps. Our focus is shifting away from simply growing our headcount to driving productivity as our reps move throughout the tenure bands. Also adding to the improvement in ADC has been the normalization of discharges as a percent of ADC. As we discussed in our Q1 call, discharge rate peaked at 39% in January and has sequentially improved versus our internal modeling since that point. To quantify how impactful discharge has been to our performance, had discharge rates mirrored 2019 experience, year-to-date June ADC would have been 874 higher, resulting in an additional $29 million in revenue and $20 million in EBITDA for the hospice segment. Now I would like to discuss Contessa's performance during the quarter. We continue to be pleased with the progress Contessa, our higher acuity segment, is making as it's generating meaningful growth in Q2 and positioning itself for material ramp in both admissions and revenue for the second half of 2022. Total emissions in Q2 for hospital and SNF at home were 345. representing year-over-year growth of 35% for Contessa. Despite the favorable growth, this performance was behind budget due to delays in closing scheduled partnerships. This volume represents 35% of the budgeted emissions missed for the quarter. Contessa is still tracking towards closing these partnerships to eventually bring this additional volume on platform. Contessa's palliative at-home model continues to demonstrate strong progress and momentum, evidenced by hitting 131% of budgeted engaged member months in the second quarter. The volume softness Contessa experienced on hospital-at-home and SNF-at-home models was partially offset by business continuing momentum towards increasingly favorable reimbursement banks. In Q2, Contessa had 30% of episodes at full risk, in 70% as limited risk compared to 21% and 79%, respectively, at the end of last year. Contesta continues to focus on finalizing health plan contracts with managed care organizations to shift volume into the full risk bucket. Contesta continues to demonstrate strong abilities to manage medical spend through its clinical management of patients admitted onto its programs. For a third straight quarter, we saw favorable direct MLR performance relative to expectations, largely due to high quality outcomes which resulted in patient satisfaction of approximately 90%. For the quarter, segment EBITDA on a consolidated basis was favorable to budget by 5%. This was driven by appropriate cost control measures at the corporate level. While volume was behind for the quarter, Contessa made meaningful strides in two key areas to bridge the gap to meet target metrics for the year. First, Contessa accelerated business development efforts by launching its previously announced partnership with Penn State Hershey and, in mid-June, closing two additional partnerships with Marquis Systems, Baylor Scott & White Health and Memorial Hermann Health System. We expect these systems to be operational by year-end. Secondly, we continue making progress on integrating the nursing function into a medicine's home health operations, as opposed to relying upon third-party home care agencies. This places the responsibility of recruiting and managing the nursing staff necessary to accept all referred patients squarely in our control. As of the close of Q2, Contessa had filled 81% of required nursing staff. thus increasing the team's ability to meet targeted emission metrics. We anticipate having this integration completed by August 1st, the one-year anniversary of closing on the acquisition of Contessa. We are confident Contessa will continue making significant progress with more partnerships as we close out the second half of the year, both with health systems as well as health plans that are interested in direct relationships. In summary, I am proud of the results we produced during the second quarter of this year. Though the environment and markets we operate in have changed, we continue to gain share, deliver the highest quality care, and differentiate ourselves. With that, I'll turn it over to Scott, who will take us through a more detailed review of our financial performance for the quarter. Scott.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-